+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Sunitinib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study



Sunitinib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study



Tumour Biology 36(1): 183-191



Sunitinib is a multitargeted tyrosine kinase inhibitor with antitumor and antiangiogenic activity. The aim of this study was to compare the efficacy of sunitinib combined with transarterial chemoembolization (TACE) versus TACE alone for treating patients with advanced-stage hepatocellular carcinoma (HCC). Of 103 patients with advanced-stage HCC, 38 (36.9 %) received TACE combined with sunitinib therapy (combined group) and the remaining 65 patients (63.1 %) received TACE alone (monotherapy group). The primary endpoint was overall survival (OS) and the secondary endpoints were time to progression (TTP) and treatment-related adverse events. Propensity score-based methods were used to minimize bias. The response rate was 15.8 % (6 of 38 patients) in the combined group and 10.8 % (7 of 65 patients) in the monotherapy group (P = 0.031). The median OS and TTP in the combined group were longer than those in the monotherapy group (OS, 8.8 vs 6.3 months; P = 0.029 and TTP, 3.9 vs 2.5 months; P = 0.002). In the propensity score-matched cohort (38 pairs), the median OS in the combined group was significantly longer than that in the monotherapy group (8.8 vs 6.5 months, respectively; P = 0.044), and the median TTP was also longer in the combined group (3.9 vs 2.6 months, respectively; P = 0.003). Significant prognostic factors for OS by multivariate analysis included the use of sunitinib, Child-Pugh scores, vascular invasion, distant organ metastasis, and serum AFP level. This study suggests that sunitinib plus TACE are superior to TACE alone with respect to OS and TTP in patients with advanced-stage HCC.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 056010107

Download citation: RISBibTeXText

PMID: 25217986

DOI: 10.1007/s13277-014-2608-3


Related references

Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study. Plos One 9(5): E96620, 2015

Combined therapy of transarterial chemoembolization and stereotactic body radiation therapy versus transarterial chemoembolization for ≤5cm hepatocellular carcinoma: Propensity score matching analysis. Plos One 13(10): E0206381, 2018

Transarterial Chemoembolization Monotherapy Versus Combined Transarterial Chemoembolization-Microwave Ablation Therapy for Hepatocellular Carcinoma Tumors ≤5 cm: A Propensity Analysis at a Single Center. Cardiovascular and Interventional Radiology 40(11): 1748-1755, 2017

Combined transarterial chemoembolization and microwave ablation versus transarterial chemoembolization in BCLC stage B hepatocellular carcinoma. Diagnostic and Interventional Radiology 24(4): 219-224, 2018

Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses. Radiology 269(2): 603-611, 2014

Comparison of treatment safety and patient survival in elderly versus nonelderly patients with advanced hepatocellular carcinoma receiving sorafenib combined with transarterial chemoembolization: a propensity score matching study. Plos One 10(2): E0117168, 2016

Transarterial Chemoembolization (TACE) Combined with Sorafenib versus TACE Alone for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Study. Journal of Cancer 10(5): 1189-1196, 2019

Comparison of hepatic resection and transarterial chemoembolization for UICC stage T3 hepatocellular carcinoma: a propensity score matching study. Bmc Cancer 18(1): 643, 2018

Transarterial chemoembolization with drug-eluting beads versus conventional transarterial chemoembolization in locally advanced hepatocellular carcinoma. Hepatic Medicine 8: 69-74, 2016

Large primary hepatocellular carcinoma: transarterial chemoembolization monotherapy versus combined transarterial chemoembolization-percutaneous microwave coagulation therapy. Journal of Gastroenterology and Hepatology 28(3): 456-463, 2013

Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching. Journal of Gastroenterology and Hepatology 31(2): 442-449, 2016

Propensity Score Matching Analysis of Changes in Alpha-Fetoprotein Levels after Combined Radiotherapy and Transarterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Plos One 10(8): E0135298, 2016

Iodine-125 implantation plus transarterial chemoembolization for the treatment of hepatocellular carcinoma of 3-5cm: A propensity score matching study. Digestive and Liver Disease 48(9): 1082-1087, 2017

Transarterial chemoembolization can prolong survival for patients with metastatic hepatocellular carcinoma: a propensity score matching analysis. Hepatology International 6(4): 753-762, 2012

Hepatic resection or transarterial chemoembolization for hepatocellular carcinoma within Milan criteria: A propensity score matching analysis. Medicine 96(51): E8933, 2018